Highlights
- ResApp developed software using smartphone-recorded cough sounds and symptom information.
- The technology originated from research at the University of Queensland.
- ResApp’s SleepCheckRx received US FDA 510(k) clearance in July 2022.
- The respiratory technology targets screening and assessment using commonly available mobile devices.
ResApp Health (ASX:RAP) developed a distinctive approach to respiratory assessment: recording cough sounds using an ordinary smartphone microphone and analysing the acoustic patterns alongside symptom information. Its research emerged from the University of Queensland and was licensed to ResApp in 2014 through university commercialisation company UniQuest. The approach sought to provide a more accessible route to screening certain respiratory conditions, but technological novelty alone does not establish clinical accuracy across all settings or applications. The evidence base, regulatory pathway and practical clinical uses are central to evaluating the company’s contribution to digital health.
From University Research to Smartphone Applications
The underlying technology was developed by Associate Professor Udantha Abeyratne and collaborators at the University of Queensland. Rather than requiring a purpose-built acoustic instrument, the concept relied on a smartphone to capture respiratory sounds and on software to interpret them. The accompanying symptom information could also inform the assessment, making the tool more than a simple cough-recording application.
Different Conditions Require Different Evidence
The historical development programme addressed respiratory conditions including asthma and pneumonia, alongside research into COVID-19 screening. These uses share cough analysis as an input but cannot be treated as interchangeable tests. A performance figure established for one algorithm, population or disease does not automatically transfer to another indication.
During 2022, the company’s proposed COVID-19 screening algorithm was subject to confirmatory data analysis in connection with a corporate transaction. The separate evaluation process highlighted the importance of sensitivity and specificity rather than relying only on statements about convenience. In clinical settings, false positives and false negatives can carry different consequences, requiring assessment against the specific purpose of a test.
A Regulatory Milestone for SleepCheckRx
In July 2022, ResApp announced that its SleepCheckRx product had received 510(k) clearance from the US Food and Drug Administration. The company said the decision permitted commercial Marketing of that test in the United States. SleepCheckRx addressed sleep-apnoea screening, which is a different application from the cough-based respiratory disease algorithms discussed elsewhere in the portfolio.
At the time, management identified employers, commercial health plans and sleep clinics as potential market channels and noted that a sales and marketing infrastructure would be needed. Clearance provides a relevant regulatory milestone, but it is not equivalent to evidence of widespread adoption or a specified Volume of clinical use. Commercial reach requires additional implementation and distribution activities.
Technology Ownership and Continuing Evidence Gaps
In September 2022, Pfizer Australia Holdings completed its Acquisition of ResApp. The University of Queensland reported total transaction value of approximately AUD 179 million. That event marked a new ownership context for the respiratory algorithms, but it does not by itself establish subsequent clinical deployments, current product availability or the outcome of any later regulatory applications.
The lasting significance of the ResApp research is its attempt to turn a widely available consumer device into a medically useful acoustic sensing tool. Assessing that contribution involves separating original research, regulatory milestones, published test characteristics and any independently confirmed clinical implementation. Where recent operating disclosures are unavailable, a historical technology review is more reliable than implying unverified new contracts or product launches.
Key Insights
ResApp’s contribution to digital health centres on smartphone acoustic analysis, condition-specific clinical testing and a US clearance for SleepCheckRx. The University of Queensland origins and subsequent Pfizer acquisition provide a documented development history. Importantly, neither a technological concept nor a transaction value demonstrates present clinical use. Verified test performance, appropriate regulation and actual implementation remain the essential distinctions.
_11_16_2026_14_23_02_796060.jpg)


_11_16_2026_11_23_12_237620.jpg)


Please wait processing your request...